Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02094300 · ClinicalTrials.gov registry record · NA
Zenith® Dissection Endovascular System
A NA study, sponsored by Cook Group Incorporated.
- Completed
- Registry status
- NA
- Development phase
- 26
- Enrollment target
NCT02094300: Completed NA study, sponsored by Cook Group Incorporated.
NCT02094300 is a NA study that has completed, run by Cook Group Incorporated. The registered enrollment target is 26 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02094300, a NA study, has completed, sponsored by Cook Group Incorporated.
- COMPLETED
- Registry status
- NA
- Development phase
- 26 participants
- Enrollment target
Study Summary
The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of patients with aortic dissection.
Primary Outcome
Major complication is defined as: Retrograde dissection, cardiac events requiring surgical management, prolonged ventilation requiring tracheotomy, renal failure requiring dialysis (where not previously needed), aortic fistula, mesenteric ischemia requiring surgical management, paralysis or paraparesis unresolved after 30 days of therapy, pulmonary embolism, stroke, and multi-system organ failure, unless related to presenting condition.
Interventions
- DEVICE Zenith® Dissection Endovascular Graft
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2007-12 |
| Est. Completion | 2016-11 |
| Phase | NA |
What the finished NCT02094300 record still lists
NCT02094300 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which Zenith® Dissection Endovascular Graft is the first listed.
NCT02094300 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02094300 about?
NCT02094300 is a clinical study titled "Zenith® Dissection Endovascular System". The Zenith® Dissection Clinical Trial is a clinical trial approved by US FDA to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of patients with aortic dissection.
What is the current status of trial NCT02094300?
This trial is currently completed. It is a NA study. The enrollment target is 26 participants. The study started on 2007-12. Estimated completion is 2016-11.
What interventions are being tested in trial NCT02094300?
The interventions under investigation include: Zenith® Dissection Endovascular Graft (DEVICE).
Who is sponsoring clinical trial NCT02094300?
This trial is sponsored by Cook Group Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02094300's enrollment target sits among peer trials
26 1710th of 2000 higher than 289 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia